In a report released today, Debjit Chattopadhyay from H.C. Wainwright maintained a Buy rating on Voyager Therapeutics Inc (VYGR), with a price target of $26. The company’s shares closed on Friday at $20.53.
Chattopadhyay noted:
“Our current target is based on a 12-year DCF analysis primarily focused on VY-AADC in PD. Our DCF analysis is based on: beta of 1.62, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 10.0%, and tax rate of 15% beginning in FY 2030.”
According to TipRanks.com, Chattopadhyay is ranked 0 out of 5 stars with an average return of -3.7% and a 38.1% success rate. Chattopadhyay covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Precision BioSciences Inc, and Mersana Therapeutics Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Voyager Therapeutics Inc with a $31.40 average price target, which is a 52.9% upside from current levels. In a report issued on August 9, Cowen & Co. also maintained a Buy rating on the stock.
See today’s analyst top recommended stocks >>
Based on Voyager Therapeutics Inc’s latest earnings release for the quarter ending June 30, the company reported a quarterly net profit of $11.15 million. In comparison, last year the company had a GAAP net loss of $25.54 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Voyager Therapeutics, Inc. operates as a clinical-stage gene therapy company, which develops treatments for patients suffering from central nervous system. Its pipeline of gene theraphy programs include VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01.
